Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProvIDHe: Open-Label Early Access Study of Ivosidenib in Pretreated Advanced Cholangiocarcinoma
jRCT2011250047Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Servier. Primary endpoints: Safety (AEs, SAEs, AESIs, discontinuations, deaths), Safety laboratory parameters and 3 more. Started Jan 2026; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2011250047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250047.